Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The companys commercialized drug products include FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; ZEVALIN injection for intravenous use as a prescription medication; and MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. It also develops BELEODAQ for the treatment of various hematological and solid tumors; Captisol-enabled MELPHALAN, an intravenous formulation of MELPHALAN for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
InPlay from Briefing.com30 Mar 2015, 4:16 pmInPlay from Briefing.com
Technical Pulse on Biotech Stocks -- Geron, Lexicon Pharma, XOMA Corp., Spectrum Pharma, and BioLine RX23 Mar 2015, 7:29 amLONDON, March 23, 2015 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Investor-Edge has initiated coverage on the following equities: Geron Corporation (NASDAQ: GERN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), XOMA Corporation (NASDAQ:...
ETF Preview: ETFs Lower, Futures Rise as Rate-Increase Fears Fade; Consumer-Sentiment Data Still Ahead13 Mar 2015, 8:32 amETF Preview: ETFs Lower, Futures Rise as Rate-Increase Fears Fade; Consumer-Sentiment Data Still Ahead
Health Care Sector Update for 03/13/2015: SPPI, ZSPH, GSK13 Mar 2015, 7:01 amHealth Care Sector Update for 03/13/2015: SPPI, ZSPH, GSK
Spectrum Pharma reports 4Q loss13 Mar 2015, 5:18 amOn a per-share basis, the Henderson, Nevada-based company said it had a loss of 5 cents. Earnings, adjusted for amortization costs and stock option expense, were 9 cents per share. The results exceeded ...
Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results13 Mar 2015, 5:00 amSpectrum Pharmaceuticals, Inc. , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and onc
Pre-Market Earnings Report for March 13, 2015 : BKE, ANN, HIBB, BTG, EBIX, RGEN, STON, PETX, TA, SPPI, CTRN, VISI12 Mar 2015, 2:16 pmPre-Market Earnings Report for March 13, 2015 : BKE, ANN, HIBB, BTG, EBIX, RGEN, STON, PETX, TA, SPPI, CTRN, VISI
Spectrum Pharmaceuticals' CE-melphalan Under Review - Analyst Blog10 Mar 2015, 3:21 pmSpectrum Pharmaceuticals' (SPPI) NDA for Captisol-enabled melphalan was accepted by the FDA for review.
ACRX Plunges On Zalviso News, CTIC Persists, HTBX On Fire, PIP Cuts Head Count10 Mar 2015, 5:46 amACRX Plunges On Zalviso News, CTIC Persists, HTBX On Fire, PIP Cuts Head Count
Spectrum Pharmaceuticals (SPPI) Stock Plunges to One-Year Low on Court's Fusilev Patent Ruling9 Mar 2015, 4:48 amNEW YORK (TheStreet) -- Shares of Spectrum Pharmaceuticals plunged more than 20% to a 52-week low of $5.65 on Monday after a U.S. District Court ruled Friday that patent claims of its Fusilev cancer drug are invalid. The U.S. District Court for the District of Nevada ruled Friday that claims 1 and 2 of Spectrum's '829 patent that covers Fusilev are invalid. Spectrum had previously sued generic ...